Literature DB >> 24077876

Impact of T cell selection methods in the success of clinical adoptive immunotherapy.

Natalia Ramírez, Lorea Beloki, Miriam Ciaúrriz, Mercedes Rodríguez-Calvillo, David Escors, Cristina Mansilla, Eva Bandrés, Eduardo Olavarría.   

Abstract

Chemotherapy and/or radiotherapy regular regimens used for conditioning of recipients of hematopoietic stem cell transplantation (SCT) induce a period of transient profound immunosuppression. The onset of a competent immunological response, such as the appearance of viral-specific T cells, is associated with a lower incidence of viral infections after haematopoietic transplantation. The rapid development of immunodominant peptide virus screening together with advances in the design of genetic and non-genetic viral- and tumoural-specific cellular selection strategies have opened new strategies for cellular immunotherapy in oncologic recipients who are highly sensitive to viral infections. However, the rapid development of cellular immunotherapy in SCT has disclosed the role of the T cell selection method in the modulation of functional cell activity and of in vivo secondary effects triggered following immunotherapy.

Entities:  

Mesh:

Year:  2014        PMID: 24077876     DOI: 10.1007/s00018-013-1463-5

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  153 in total

1.  Safer CARS.

Authors:  Helen E Heslop
Journal:  Mol Ther       Date:  2010-04       Impact factor: 11.454

Review 2.  Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Immunol Rev       Date:  1997-06       Impact factor: 12.988

Review 3.  Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

Authors:  Pawel Muranski; Andrea Boni; Claudia Wrzesinski; Deborah E Citrin; Steven A Rosenberg; Richard Childs; Nicholas P Restifo
Journal:  Nat Clin Pract Oncol       Date:  2006-12

4.  Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation.

Authors:  Fabio Ciceri; Chiara Bonini; Sarah Marktel; Elisabetta Zappone; Paolo Servida; Massimo Bernardi; Alessandra Pescarollo; Attilio Bondanza; Jacopo Peccatori; Silvano Rossini; Zulma Magnani; Monica Salomoni; Claudia Benati; Maurilio Ponzoni; Luciano Callegaro; Paolo Corradini; Marco Bregni; Catia Traversari; Claudio Bordignon
Journal:  Blood       Date:  2007-02-27       Impact factor: 22.113

5.  Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.

Authors:  Sergio A Quezada; Tyler R Simpson; Karl S Peggs; Taha Merghoub; Jelena Vider; Xiaozhou Fan; Ronald Blasberg; Hideo Yagita; Pawel Muranski; Paul A Antony; Nicholas P Restifo; James P Allison
Journal:  J Exp Med       Date:  2010-02-15       Impact factor: 14.307

Review 6.  Adoptive immunotherapy for posttransplantation viral infections.

Authors:  Catherine M Bollard; Ingrid Kuehnle; Ann Leen; Cliona M Rooney; Helen E Heslop
Journal:  Biol Blood Marrow Transplant       Date:  2004-03       Impact factor: 5.742

7.  Cytomegalovirus-specific T cell immunotherapy promotes restoration of durable functional antiviral immunity following allogeneic stem cell transplantation.

Authors:  Karl S Peggs; Stephanie Verfuerth; Arnold Pizzey; Shoon-Ling C Chow; Kirsty Thomson; Stephen Mackinnon
Journal:  Clin Infect Dis       Date:  2009-12-15       Impact factor: 9.079

8.  Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.

Authors:  Concetta Quintarelli; Juan F Vera; Barbara Savoldo; Greta M P Giordano Attianese; Martin Pule; Aaron E Foster; Helen E Heslop; Cliona M Rooney; Malcolm K Brenner; Gianpietro Dotti
Journal:  Blood       Date:  2007-07-17       Impact factor: 22.113

9.  Do CD8 effector cells need IL-7R expression to become resting memory cells?

Authors:  Eva Buentke; Anne Mathiot; Mauro Tolaini; James Di Santo; Rose Zamoyska; Benedict Seddon
Journal:  Blood       Date:  2006-05-16       Impact factor: 22.113

10.  Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.

Authors:  Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas C Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2005-10-03       Impact factor: 14.307

View more
  4 in total

Review 1.  The immune response to cytomegalovirus in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Miriam Ciáurriz; Amaya Zabalza; Lorea Beloki; Cristina Mansilla; Estela Pérez-Valderrama; Mercedes Lachén; Eva Bandrés; Eduardo Olavarría; Natalia Ramírez
Journal:  Cell Mol Life Sci       Date:  2015-07-15       Impact factor: 9.261

2.  Assessment of the effector function of CMV-specific CTLs isolated using MHC-multimers from granulocyte-colony stimulating factor mobilized peripheral blood.

Authors:  Lorea Beloki; Miriam Ciaurriz; Cristina Mansilla; Amaya Zabalza; Estela Perez-Valderrama; Edward R Samuel; Mark W Lowdell; Natalia Ramirez; Eduardo Olavarria
Journal:  J Transl Med       Date:  2015-05-20       Impact factor: 5.531

3.  CMV-specific T cell isolation from G-CSF mobilized peripheral blood: depletion of myeloid progenitors eliminates non-specific binding of MHC-multimers.

Authors:  Lorea Beloki; Miriam Ciaurriz; Cristina Mansilla; Amaya Zabalza; Estela Perez-Valderrama; Edward R Samuel; Mark W Lowdell; Natalia Ramirez; Eduardo Olavarria
Journal:  J Transl Med       Date:  2014-11-19       Impact factor: 5.531

4.  Cytotoxic Activity and Memory T Cell Subset Distribution of in vitro-Stimulated CD8+ T Cells Specific for HER2/neu Epitopes.

Authors:  Maria Kuznetsova; Julia Lopatnikova; Julia Shevchenko; Alexander Silkov; Amir Maksyutov; Sergey Sennikov
Journal:  Front Immunol       Date:  2019-05-09       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.